Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 06, 2016 7:09 PM ET

Biotechnology

Company Overview of Premune AB

Company Overview

Premune AB, an animal health company, develops treatments for allergies, inflammatory bowel diseases, and other immune disorders in pets worldwide. Its developments are targeting problem areas in veterinary medicine. The company was founded in 2009 and is based in Stockholm, Sweden.

Kungsgatan 3 vån 4

Stockholm,  111 43

Sweden

Founded in 2009

Phone:

46 7 60 26 52 69

Key Executives for Premune AB

Co-Founder and Chief Executive Officer
Chief Operating Officer
Head of Licensing & Regulatory Affairs and Director
Age: 63
Head of Clinical Development
Head of Regulatory Affairs
Compensation as of Fiscal Year 2015.

Premune AB Key Developments

Premune Appoints Ed Torr as Head of Business Development and Commercial Operations

Premune announced the appointment of Ed Torr as Head of Business Development and Commercial Operations, effective September 7, 2015. Mr. Torr, who will be based in the UK, will oversee Premune's commercialization and business development efforts as the company prepares for its initial product launches. Ed brings more than 30 years of experience in animal health with senior leadership roles in some of the most prominent animal health companies in Europe including ICI, Coopers Animal Health, Alfa Laval Agri and Dechra Pharmaceuticals PLC. He was an executive director of Dechra Pharmaceuticals PLC from 2000-2014 during which time he had responsibility for business development, manufacturing and product development, Dechra Veterinary Products Europe and geographical expansion.

Premune AB Enters into Licensing Agreement with Innovet Italia s.r.l

Premune AB and Innovet Italia s.r.l. have entered into an exclusive licensing agreement for Redonyl (R) Ultra. Redonyl (R) Ultra is a nutritional supplement based on PEA-um (R) (ultramicronized palmitoylethanolamide) to support healthy skin in dogs and cats.

Premune AB Presents at 8th Annual OneMedForum 2015, Jan-12-2015 03:15 PM

Premune AB Presents at 8th Annual OneMedForum 2015, Jan-12-2015 03:15 PM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: Viktor Karlsson, Co-Founder and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
Folitech AB Europe
Mabtech AB Europe
Siem Capital AB Europe
Biostapro AB Europe
MIAB SA Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Premune AB, please visit www.premune.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.